Senti Biosciences Holdings, Inc. (NasdaqCM: SNTI)
Health Care · Biotechnology · US
$0.38
-2.73% today · -75.6% 1Y
Senti Biosciences Holdings, Inc. (NasdaqCM: SNTI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $12.10M and employs 39 people.
Over the last twelve months the share price has lost 75.6%, trading between 0.33 and 2.88.
Tweenvest scores Senti Biosciences Holdings, Inc. across four factors: quality 12/100, value 25/100. Its strongest factor is value.
SNTI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.10M
- Revenue (TTM)
- $55.00K
- P/E
- —
- EPS
- -1.71
- Dividend yield
- —
- Beta (5Y)
- 2.11
- 52-week high
- $2.88
- 52-week low
- $0.33
- Avg volume (3M)
- —
- Shares outstanding
- 31.14M
- Employees
- 39
- Next earnings
- —
About Senti Biosciences Holdings, Inc.
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
- ISIN
- US8169441024
- Founded
- 2016
- Listed since
- May 26, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.03 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.34 | +2.48% |
Figures last refreshed Aug 18, 2026.